Dual agonists of DR4 and DR5 have been developed that activate both receptors, initiating the apoptotic death of cancer cells, while circumventing decoy receptor involvement. These agents demonstrate notable preclinical pro-apoptotic effects (Milutinovic et al., 2016). The gene discussed is TNFRSF10A; the disease is cancer.